EGFR and non-small cell lung carcinoma: There have been preclinical studies suggesting that monotherapy with osimertinib is not effective for the treatment of EGFR mutant NSCLC with acquired resistance to first-, second-, or third-generation EGFR-TKIs, due to MET amplification, or even MET hyperactivation [27].